report_lead_image_with_gradient.png
2025

APAC Healthcare Market Snapshot

Download this Report
To download this report, please complete the form below

PitchBook clients can access this report’s Excel data pack via the Research Center on the PitchBook Platform.

A biopharma boom in China, India’s growing healthtech hub, and big buyouts in Japan

The Asia-Pacific region presents immense opportunities for healthcare investors, as massive populations, developing private markets, and government-led initiatives are driving innovation across the region’s healthcare systems and medical technology. China’s biopharma sector has firmly positioned itself among global leaders in therapeutic innovation leading to several multibillion-dollar licensing agreements between domestic drug developers and international pharma giants. Meanwhile, India’s rapidly developing VC ecosystem is powering an emerging healthtech hub, and PE investors have deployed billions into Japanese markets.

After peaking in 2021, healthcare VC activity has moderated in the Asia-Pacific region, with recent funding consolidating in biopharma and medtech startups. However, large deals for India’s PB Healthcare and Vietnam’s Nhi Dong 315 demonstrate continued opportunities in developing healthcare systems. PE investment remains relatively strong, supported by large deals in Japan and Australia. As investors recalibrate to a shifting landscape, APAC’s diverse markets continue to offer opportunities for growth and technological innovation.


Table of contents
Commentary 1
City comparison 4
Public markets 5
VC activity 6
PE activity 9